Literature DB >> 20840845

The selective dopamine uptake inhibitor, D-84, suppresses cocaine self-administration, but does not occasion cocaine-like levels of generalization.

Angela M Batman1, Aloke K Dutta, Maarten E A Reith, Patrick M Beardsley.   

Abstract

A successful replacement pharmacotherapy for treating cocaine dependency would likely reduce cocaine's abuse, support a low abuse liability, overlap cocaine's subjective effects, and have a long duration of action. Inhibitors with varying selectivity at the dopamine transporter (DAT) have approximated these properties. The objective of the present study was to characterize the behavioural effects of an extremely selective DAT inhibitor, (+) trans-4-(2-Benzhydryloxyethyl)-1-(4-fluorobenzyl) piperadin-3-ol (D-84), a 3-hydroxy substituted piperidine derivative of GBR-12935, for its cocaine-like discriminative stimulus effects, its effects on cocaine self-administration, and for its own self-administration. During cocaine discrimination tests, cocaine occasioned the 10 mg/kg cocaine training stimulus with an ED(50) value of 3.13 (1.54-6.34) mg/kg, and reduced response rates with an ED(50) value of 20.39 (7.24-57.44) mg/kg. D-84 incompletely generalized to the cocaine stimulus occasioning a maximal 76% cocaine-lever responding, while reducing response rates with lower potency than cocaine (ED(50)=30.94 (12.34-77.60) mg/kg). Pretreatment with D-84 (9.6-30.4 mg/kg) significantly (P<0.05) reduced cocaine intake at 17.1 mg/kg D-84 when cocaine was self-administered at 0.5 mg/kg/infusion, and at 30.4 mg/kg D-84 when cocaine was self-administered at 0.1, 0.5 .and 1.0 mg/kg/infusion. During self-administration tests with D-84 (0.1-1 mg/kg/infusion), numbers of infusions significantly exceeded vehicle levels at 0.3 mg/kg/infusion. These results show that D-84 pretreatment can decrease cocaine intake especially when high doses of cocaine are being self-administered. This observation, combined with its incomplete generalization to the cocaine discriminative stimulus and its reported long duration of action, provides a profile consistent with a potential replacement therapy for treating cocaine-abusing patients.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20840845      PMCID: PMC2953608          DOI: 10.1016/j.ejphar.2010.08.051

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  21 in total

1.  Assessment of fetal lung volumes and liver herniation with magnetic resonance imaging in congenital diaphragmatic hernia.

Authors:  D S Walsh; A M Hubbard; O O Olutoye; L J Howell; T M Crombleholme; A W Flake; M P Johnson; N S Adzick
Journal:  Am J Obstet Gynecol       Date:  2000-11       Impact factor: 8.661

2.  Effects of N-substituted analogs of benztropine: diminished cocaine-like effects in dopamine transporter ligands.

Authors:  Jonathan L Katz; Theresa A Kopajtic; Gregory E Agoston; Amy Hauck Newman
Journal:  J Pharmacol Exp Ther       Date:  2004-01-30       Impact factor: 4.030

3.  High affinity hydroxypiperidine analogues of 4-(2-benzhydryloxyethyl)-1-(4-fluorobenzyl)piperidine for the dopamine transporter: stereospecific interactions in vitro and in vivo.

Authors:  Sujit K Ghorai; Charles Cook; Matthew Davis; Sylesh K Venkataraman; Clifford George; Patrick M Beardsley; Maarten E A Reith; Aloke K Dutta
Journal:  J Med Chem       Date:  2003-03-27       Impact factor: 7.446

Review 4.  Substitution management in opioid dependence.

Authors:  A Uchtenhagen
Journal:  J Neural Transm Suppl       Date:  2003

5.  Interaction of noncontingent cocaine and contingent drug-paired stimuli on cocaine reinstatement.

Authors:  Keith L Shelton; Elizabeth Hendrick; Patrick M Beardsley
Journal:  Eur J Pharmacol       Date:  2004-08-16       Impact factor: 4.432

6.  Structural requirements for cocaine congeners to interact with dopamine and serotonin uptake sites in mouse brain and to induce stereotyped behavior.

Authors:  M E Reith; B E Meisler; H Sershen; A Lajtha
Journal:  Biochem Pharmacol       Date:  1986-04-01       Impact factor: 5.858

7.  Dopamine transporter binding without cocaine-like behavioral effects: synthesis and evaluation of benztropine analogs alone and in combination with cocaine in rodents.

Authors:  J L Katz; G E Agoston; K L Alling; R H Kline; M J Forster; W L Woolverton; T A Kopajtic; A H Newman
Journal:  Psychopharmacology (Berl)       Date:  2001-04       Impact factor: 4.530

8.  Self-administration of cocaine: scopolamine combinations by rhesus monkeys.

Authors:  Robert Ranaldi; William L Woolverton
Journal:  Psychopharmacology (Berl)       Date:  2002-04-24       Impact factor: 4.530

9.  Assessment of reinforcing effects of benztropine analogs and their effects on cocaine self-administration in rats: comparisons with monoamine uptake inhibitors.

Authors:  Takato Hiranita; Paul L Soto; Amy H Newman; Jonathan L Katz
Journal:  J Pharmacol Exp Ther       Date:  2009-02-19       Impact factor: 4.030

10.  Comparison of inhibition of monoamine uptake by cocaine, methylphenidate and amphetamine.

Authors:  D Taylor; B T Ho
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1978-07
View more
  2 in total

1.  Novel multifunctional pharmacology of lobinaline, the major alkaloid from Lobelia cardinalis.

Authors:  Dustin P Brown; Dennis T Rogers; Francois Pomerleau; Kirin B Siripurapu; Manish Kulshrestha; Greg A Gerhardt; John M Littleton
Journal:  Fitoterapia       Date:  2016-04-20       Impact factor: 2.882

2.  The atypical stimulant and nootropic modafinil interacts with the dopamine transporter in a different manner than classical cocaine-like inhibitors.

Authors:  Kyle C Schmitt; Maarten E A Reith
Journal:  PLoS One       Date:  2011-10-17       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.